

III. 研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
Ohno K , Ohkawara B, Ito M, Engel AG.	Molecular Genetics of Congenital Myasthenic Syndromes		<i>eLS</i>	John Wiley & Sons, Inc.	Chichester	2014	http://www.els.net [doi: 10.1002/9780470015902.a0024314]. (査読有)
Ohno K , Ito M, Kawakami Y, Ohtsuka K.	Collagen Q is a key player for developing rational therapy for congenital myasthenia and for dissecting the mechanisms of anti-MuSK myasthenia gravis		<i>J Mol Neurosci</i>			2014	53: 359-361. (査読有)
Noda M, Fujita K, Ohsawa I, Ito M, Ohno K .	Multiple effects of molecular hydrogen and its distinct mechanism		<i>J Neurol Disord</i>			2014	2: 6 (査読有)
Noda M, Ito M, Ohsawa I, Ohno K .	Beneficial effects of hydrogen in the CNS and a new brain-stomach interaction		<i>Eur J Neurodegener Dis</i>			2014	3: 25-34 (査読有)
Rahman MA, Nasrin F, Masuda A, Ohno K .	Decoding abnormal splicing code in human diseases		<i>J Invest Genomics</i>			2015	2(1): 00016 (査読有)

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Inaguma Y, Hamada N, Tabata H, Iwamoto I, Mizuno M, Nishimura YV, Ito H, Morishita R, Suzuki M, Ohno K , Kumagai T, Nagata KI.	SIL1, a causative cochaperone gene of Marinesco-Sjogren syndrome, plays an essential role in establishing the architecture of the developing cerebral cortex	<i>EMBO Mol Med</i>	6	155 - 295	2014
Ohkawara B, Cabrera-Serrano M, Nakata T, Milone M, Asai N, Ito K, Ito M, Masuda A, Ito Y, Engel AG, Ohno K .	LRP4 third beta-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner	<i>Hum Mol Genet</i>	23	1856-1868	2014
Nakayama T, Nakamura H, Oya Y, Kimura T, Imahuku I, Ohno K , Nishino I, Abe K, Matsuura T.	Clinical and genetic analysis of the first known Asian family with myotonic dystrophy type 2	<i>J Hum Genet</i>	59	129-133	2014

Kokunai Y*, Nakata T*, Furuta M*, Sakata S, Kimura H, Aiba T, Yoshinaga M, Osaki Y, Nakamori M, Itoh H, Sato T, Kubota T, Kadota K, Shindo K, Mochizuki H, Shimizu W, Horie M, Okamura Y, Ohno K , Takahashi M. *Equal contribution.	A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1	<i>Neurology</i>	82	1058-1064	2014
Mano Y, Kotani T, Ito M, Nagai T, Ichinohashi Y, Yamada K, Ohno K , Kikkawa F, Toyokuni S.	Maternal molecular hydrogen administration ameliorates rat fetal hippocampal damage caused by in utero ischemia-reperfusion	<i>Free Radic Biol Med</i>	69	324-330	2014
Takamatsu A, Ohkawara B, Ito M, Masuda A, Sakai T, Ishiguro N, Ohno K .	Verapamil protects against cartilage degradation in osteoarthritis by inhibiting Wnt/ β -catenin signaling	<i>PLOS ONE</i>	9	e92699	2014
Kobayashi M, Ohno T, Ihara K, Murai A, Kumazawa M, Hoshino H, Iwanaga K, Iwai H, Hamana Y, Ito M, Ohno K , Horio F.	Searching for genomic region of high-fat diet-induced type 2 diabetes in mouse chromosome 2 by analysis of congenic strains	<i>PLOS ONE</i>	9	e96271	2014
Yamashita Y*, Matsuura T*, Kurosaki T, Amakusa Y, Kinoshita M, Ibi T, Sahashi K, Ohno K . *Equal contribution.	LDB3 splicing abnormalities are specific to skeletal muscles of patients with myotonic dystrophy type 1 and alter its PKC binding affinity	<i>Neurobiol Disord</i>	69	200-205	2014
Asai N, Ohkawara B, Ito M, Masuda A, Ishiguro N, Ohno K	LRP4 induces extracellular matrix productions and facilitates chondrocyte differentiation	<i>Biochem Biophys Res Commun</i>	451	302-307	2014
Nasrin F, Rahman MA, Masuda A, Ohe K, Takeda J, Ohno K .	HnRNP C, YB-1 and hnRNP L coordinately enhance skipping of human MUSK exon 10 to generate a Wnt-insensitive MuSK isoform.	<i>Sci Rep</i>	4	6841	2014
Nishizaki, Y., Takagi, T., Matsui, F. and Higashi, Y.	SIP1 expression patterns in brain investigated by generating a SIP1-EGFP reporter knock-in mouse	<i>Genesis</i>	52	56-67	2014
Kimura, M., Machida, J., Yamaguchi, S., Shibata, S., Tatematsu, T., Miyachi, H., Peter A. Jezewski, P. A., Nakayama, A., Higashi, Y. , Shimoizato, K. and Tokita, Y.	Novel nonsense mutation in MSX1 in familial nonsyndromic oligodontia: subcellular localization and role of homeodomain/MH4	<i>Eur J Oral Sci</i>	122	15-20	2014
Yamaguchi S, Machida J, Kamamoto M, Kimura M, Shibata A, Tatematsu T, Miyachi H, Higashi Y , Jezewski P, Nakayama A, Shimoizato K, Tokita Y.	Characterization of novel MSX1 mutations identified in Japanese patients with nonsyndromic tooth agenesis.	<i>PLoS One</i>	9	e102944	2014

Zhang Y, <u>Haga N.</u>	Skeletal complications in congenital insensitivity to pain with anhidrosis: a case series of 14 patients and review of articles published in Japanese	<i>J Orthop Sci</i>	19	827-831	2014
Okabe YT, Kondo T, Mishima K, Hayase Y, Kato K, Mizuno M, Ishiguro N, <u>Kitoh H.</u>	Biodistribution of locally or systemically transplanted osteoblast-like cells.	<i>Bone Joint Res</i>	3	76-81	2014
Azuma Y, Nakata T, Tanaka M, Shen XM, Ito M, Iwata S, Okuno T, Nomura Y, Ando N, Ishigaki K, Ohkawara B, Masuda A, Natsume J, Kojima S, Sokabe M, <u>Ohno K.</u>	Congenital myasthenic syndrome in Japan: Ethnically unique mutations in muscle nicotinic acetylcholine receptor subunits	<i>Neuromuscular Disorders</i>	25	60-69	2015
Matsushita M, Hasegawa S, Kitoh H, Mori K, Ohkawara B, Yasoda A, Masuda A, Ishiguro N, <u>Ohno K.</u>	Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.	<i>Endocrinology</i>	156	548-554	2015
Funayama M, Ohe K, Amo T, Furuya N, Yamaguchi J, Saiki S, Li Y, Ogaki K, Ando M, Yoshino H, Tomiyama H, Nishioka K, Hasegawa K, Saiki H, Satake W, Mogushi K, Sasaki R, Kokubo Y, Kuzuhara S, Toda T, Mizuno Y, Uchiyama Y, <u>Ohno K.</u> , Hattori N.	CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study	<i>Lancet Neurol</i>	14	274-282	2015
Tsunoda M, Hirayama M, Tsuda T, <u>Ohno K.</u>	Noninvasive monitoring of plasma l-dopa concentrations using sweat samples in Parkinson's disease	<i>Clin Chim Acta</i>	442	52-55	2015
Sobue S, Yamai K, Ito M, <u>Ohno K.</u> , Iwamoto T, Qiao S, Ohkuwa T, Ichihara M.	Simultaneous oral and inhalational intake of molecular hydrogen additively suppresses signaling pathways in rodents	<i>Mol Cell Biochem</i>	403	231-241	2015
Masuda A, Takeda J, Okuno T, Okamoto T, Ohkawara B, Ito M, Ishigaki S, Sobue G, <u>Ohno K.</u>	Position-specific binding of FUS to nascent RNA regulates mRNA length	<i>Genes Dev</i>	29	1045-1057	2015
Selcen D, Ohkawara B, Shen X-M, McEvoy K, <u>Ohno K.</u> , Engel AG.	LRP4 myasthenia. Impaired Synaptic Development, Maintenance, and Neuromuscular Transmission in LRP4 Myasthenia	<i>JAMA Neurology</i>		in press	
Udagawa T, Fujioka Y, Tanaka M, Honda D, Yokoi S, Riku Y, Ibi D, Nagai T, Yamada K, Watanabe H, Katsuno M, Inada T, <u>Ohno K.</u> , Sokabe M, Okado H, Ishigaki S, Sobue G.	FUS regulates AMPA receptor function and FTL/ALS-associated behavior via GluA1 mRNA stabilization	<i>Nat Commun</i>		in press	
Fujii H, Matsubara K, Sakai K, Ito M, <u>Ohno K.</u> , Ueda M, Yamamoto A.	Dopaminergic differentiation of stem cells from Human deciduous teeth and their therapeutic benefits for parkinsonian rats	<i>Brain Res</i>		in press	
Iwata S, Ito M, Nakata T, Noguchi Y, Okuno T, Ohkawara B, Masuda A, Goto T, Adachi M, Osaka H, Nonaka R, Arikawa-Hirasawa E, <u>Ohno K.</u>	A missense mutation in domain III in <i>HSPG2</i> in Schwartz-Jampel syndrome compromises secretion of perlecan into the extracellular space	<i>Neuromuscular Disorders</i>		in press	

Kishimoto Y, Kato T, Ito M, Azuma Y, Fukasawa Y, <u>Ohno K</u> , Kojima S.	Molecular hydrogen ameliorates monocrotaline-induced pulmonary hypertension in rats by modulating the STAT3/NFAT axis with anti-inflammatory and anti-oxidative effects	<i>J Thorac Cardiovasc Surg</i>		in press	
<u>柳田晴久</u>	症候性側弯症	小児科診療	Vol.78 No.4, 2015	529-535	2015

研究成果の刊行物・別刷

LRP4 third β -propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner

Bisei Ohkawara¹, Macarena Cabrera-Serrano³, Tomohiko Nakata¹, Margherita Milone³, Nobuyuki Asai¹, Kenyu Ito¹, Mikako Ito¹, Akio Masuda¹, Yasutomo Ito², Andrew G. Engel^{3,*} and Kinji Ohno^{1,*}

¹Division of Neurogenetics, Center for Neurological Diseases and Cancer and ²Division for Medical Research Engineering, Nagoya University Graduate School of Medicine, Nagoya, Japan ³Department of Neurology, Mayo Clinic, Rochester, MN, USA

Received June 10, 2013; Revised October 15, 2013; Accepted November 11, 2013

Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Using Sanger and exome sequencing in a CMS patient, we identified two heteroallelic mutations, p.Glu1233Lys and p.Arg1277His, in *LRP4* coding for the postsynaptic low-density lipoprotein receptor-related protein 4. *LRP4*, expressed on the surface of the postsynaptic membrane of the neuromuscular junction, is a receptor for neurally secreted agrin, and *LRP4* bound by agrin activates MuSK. Activated MuSK in concert with Dok-7 stimulates rapsyn to concentrate and anchor AChR on the postsynaptic membrane and interacts with other proteins implicated in the assembly and maintenance of the neuromuscular junction. *LRP4* also functions as an inhibitor of Wnt/beta-catenin signaling. The identified mutations in *LRP4* are located at the edge of its 3rd beta-propeller domain and decrease binding affinity of *LRP4* for both MuSK and agrin. Mutations in the *LRP4* 3rd beta-propeller domain were previously reported to impair Wnt signaling and cause bone diseases including Cenani–Lenz syndactyly syndrome and sclerosteosis-2. By analyzing naturally occurring and artificially introduced mutations in the *LRP4* 3rd beta-propeller domain, we show that the edge of the domain regulates the MuSK signaling whereas its central cavity governs Wnt signaling. We conclude that *LRP4* is a new CMS disease gene and that the 3rd beta propeller domain of *LRP4* mediates the two signaling pathways in a position-specific manner.

INTRODUCTION

Congenital myasthenic syndromes (CMS) are diverse disorders in which the safety margin of neuromuscular transmission is compromised by deficiency or abnormal function of an endplate (EP)-associated protein. To date, mutations in no fewer than 17 genes coding for proteins expressed at EP are known to cause CMS (1): *ALG2* (MIM 607905), *ALG14* (MIM 612866), *CHRNA1* (MIM 100690), *CHRNB1* (MIM 100710), *CHRND*

(MIM 100720), *CHRNE* (MIM 100725), *AGRN* (MIM 103320), *CHAT* (MIM 118491), *DPAGT1* (MIM 191350), *GFPT1* (MIM 138292), *LAMB2* (MIM 150325), *PLEC* (MIM 601282), *MUSK* (MIM 601296), *RAPSN* (MIM 601592), *COLQ* (MIM 603033), *SCN4A* (MIM 603967) and *DOK7* (MIM 610285). We here describe our findings in a novel CMS caused by mutations in the low-density lipoprotein receptor-related protein 4 encoded by *LRP4*.

EP development is triggered by the binding of agrin released from the nerve terminal to *LRP4*, a transmembrane protein of the

*To whom correspondence should be addressed at: Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, Aichi 466-8550, Japan. Tel: +81 52 744 2446; Fax: +81 52 744 2449; Email: ohnok@med.nagoya-u.ac.jp (K.O.); Neuromuscular Research Laboratory, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Tel: +1 507 284 5102; Fax: +1 507 284 5831; Email: age@mayo.edu (A.G.E.)

postsynaptic membrane (2,3). LRP4 bound to agrin forms a ternary complex with the postsynaptic transmembrane muscle-specific receptor tyrosine kinase (MuSK). In this complex, the 3rd β -propeller domain of LRP4 is important for association with MuSK (4), although the interacting conformations remain unresolved. Binding of LRP4 to MuSK triggers phosphorylation and activation of the MuSK intracellular kinase domain. Activated MuSK in concert with Dok-7 stimulates rapsyn to concentrate and anchor AChR in the postsynaptic membrane and to interact with other proteins implicated in the assembly and maintenance of the NMJ (5). LRP4 was recently reported to provide a retrograde signal for presynaptic differentiation at neuromuscular junction (6,7). In addition, autoantibodies directed against LRP4 were recently recognized to cause a form of autoimmune myasthenia gravis (8–10).

In addition to its specific role at the NMJ, LRP4 is also a well-characterized inhibitor of the Wnt-signaling pathway. LRP4 signaling is involved in skeleton formation and kidney development. Mutations in *LRP4* have been reported in Cenani–Lenz syndactyly syndrome (CLSS) (11), sclerosteosis-2 (12), and low bone mineral density in human (13) and mice (14). Similarly, *Lrp4* mutations cause mule foot disease in cow (15) and kidney and limb defects in mouse (16). In addition, a missense SNP rs2306029 in *LRP4* is associated with 4.17-fold increase in the risk of developing Richter syndrome (17). To date, no report has implicated *LRP4* as a CMS disease gene.

Using Sanger and exome-capture resequencing, we identified two heteroallelic missense variants in *LRP4*, p.Glu1233Lys (c.3697G > A) and p.Arg1277His (c.3830G > A). Both variants are located at the edge of the 3rd β -propeller domain of LRP4. We show that each variant impairs binding ability of LRP4 for both agrin and MuSK as well as subsequent agrin-mediated phosphorylation and activation of MuSK, but neither mutation affects the Wnt-signaling pathway. Finally, by analysis of mutations in other diseases and by examining effects of artificially engineered mutations into the 3rd LRP4 β -propeller domain, we show the edge of this domain mediates the MuSK signaling, whereas its central cavity mediates the Wnt signaling.

RESULTS

Clinical data

The patient was born after 42 weeks of gestation with fetal distress and with Apgar scores of 3 and 6 at 1 and 5 min, respectively. Immediately after birth, she had a respiratory arrest and required hospitalization for feeding and respiratory support

until the age of 6 months. She started to walk at 18 months but could only walk short distances. During childhood, she fatigued abnormally, could not climb step and was partially wheelchair dependent. Examination at the Mayo Clinic at ages 9 and 14 years revealed mild eyelid ptosis, slight limitation of lateral eye movements, moderately severe proximal greater than distal muscle weakness and hypoactive tendon reflexes. Repetitive nerve stimulation of the spinal accessory nerve showed a 13–16% decrement of the fourth compared with the first compound muscle action potential evoked from the trapezius, biceps and rectus femoris muscles with no significant decrement in the anterior tibial muscle. The decremental responses were transiently improved by edrophonium chloride, a fast acting cholinergic agonist. However, therapy for a few days with pyridostigmine at age 12 markedly worsened the patient's weakness. There was no history of similarly affected family members.

Endplate studies

An intercostal muscle specimen was obtained from the patient at age 17 years. Routine histologic examination revealed type 1 fiber preponderance. Synaptic contacts, examined in face-on views of glutaraldehyde-fixed AChE-reacted teased muscle fibers revealed multiple irregularly arrayed synaptic contacts that varied in shape and size (Fig. 1). None of the EPs had a normal pretzel shape. Electron microscopy examination of 54 EP regions of 29 EPs showed that the structural integrity of the nerve terminals and postsynaptic regions was preserved but quantitative analysis revealed that the size of the nerve terminals was reduced to 60%, and that of the postsynaptic region to 48%, of the corresponding control value (Table 1).

Immunofluorescence microscopy examination of frozen sections revealed normal expression of AChR and AChE at patient EPs. Ultrastructural localization of AChR at the EPs with peroxidase-labeled α -bungarotoxin (bgt) demonstrated normal distribution and density of AChR on the junctional folds. However, the total number of AChRs per EP fell slightly below the range of control values (Table 1).

The MEPP amplitude and the number of quanta released by nerve impulse fell in the normal range, and patch-clamp recordings from 10 EPs revealed normal kinetics of the AChR channel (data not shown).

Sanger and exome-capture resequencing analysis

We analyzed the patient DNA using the exome-capture resequencing analysis. The number of SOLiD tags was 90.7×10^6




Figure 1. Synaptic contacts in intercostal muscle visualized by the cholinesterase reaction. (A) Normal EP. (B–D) Patient EPs. Note irregularly arrayed pleomorphic synaptic contacts at patient EPs. Bar in (A) indicates 50 μ m. Bar in (D) indicates 50 μ m for panels (B–D).

Table 1. Quantitative analysis of EP ultrastructure and [¹²⁵I]α-bungarotoxin-binding sites per EP

	Patient	Controls	P-value
Nerve terminal area (μm ²)	2.45 ± 0.30 (54)	3.88 ± 0.39 (63)	<0.005
Postsynaptic area (μm ²)	5.51 ± 0.45 (54)	10.6 ± 0.79 (59)	<0.001
[¹²⁵ I]α-bgt-binding sites/EP	8.7 × 10 ⁶	12.82 ± 0.79 × 10 ⁶ (13) Range: 9.3–18.7	

Values represent mean ± SE. More than one region can occur at an EP. Values in parenthesis represent number of EP regions except for [¹²⁵I]α-bgt-binding sites where they indicate number of subjects. P-values are based on *t*-test.

spanning 4.53 Gb, and 72.8 × 10⁶ tags (80.2%) spanning 3.47 Gb (76.6%) were mapped to the human genome hg19/GRCh37. As the SureSelect probes span 38 Mb, the mean coverage became 91.4. Among the 38-Mb SureSelect probe regions, 3.9% of nucleotides were not covered by any tags. Search for SNVs and indels using Avadis NGS with default parameters detected 46 555 SNVs/indels. We eliminated SNVs/indels registered in dbSNP137 and those with unreliable calls (Avadis decibel score ≤200), and obtained 4074 SNVs/indels. Restriction of our analysis to non-synonymous, frameshifting and splicing SNVs/indels in 33 candidate genes that are essential for the neuromuscular signal transmission yielded three SNVs. Among the three SNVs, a heterozygous c.1148C > G SNV predicting p.Ser376Arg in *SNTB2* encoding syntrophin β₂ was observed in a patient with periodic paralysis among our cohort of 31 patients other than CMS. In addition, 13 other missense SNPs and two frameshifting SNPs are registered in 539 codons encoded by *SNTB2* in dbSNP137. Thus, p.Ser376Arg in *SNTB2* was unlikely to be pathogenic. The two other SNVs were heterozygous c.3697G > A (chr11: 46 897 357) and c.3830G > A (chr11: 46 897 102) in *LRP4*, which predicted p.Glu1233Lys (EK mutation) and p.Arg1277His (RH mutation), respectively. Sanger sequencing of the patient's genomic DNA and mRNA confirmed both mutations and sequencing of cloned mRNA indicated that the mutations were heteroallelic. The father was heterozygous for p.Glu1233Lys. A half brother carried no mutation. No DNA was available from the mother. According to the PolyPhen-2 (18), SIFT (19) and Mutation Taster (20) algorithms, the predicted consequences of the EK mutation were 'benign', 'tolerated' and 'disease causing with *P* > 0.99999', respectively. Those of the RH mutation were 'probably damaging', 'affect protein function' and 'disease causing with *P* > 0.99999', respectively. LRP4 is a transmembrane protein with large extracellular domains (Fig. 2A). These mutations were in the 3rd low-density lipoprotein receptor (LDLR) type B repeat, known as β-propeller-like structure. The EK and RH mutations are downstream of the 4th and 5th YWTD motifs, respectively (Fig. 2B). The YWTD motifs are predicted to form the second β sheet below the surface β sheet of each blade of the 3rd β-propeller domain, and the mutations are at the linker between the surface β sheet and the second β sheet.

The EK and RH mutations in *LRP4* impair the MuSK signaling pathway


During the NMJ formation, binding of agrin to LRP4 induces phosphorylation and activation of MuSK, which activates ATF2 downstream of JNK and induces clustering of AChR. To study effects of the mutations in this signaling pathway, we used a JNK-responsive ATF2-luciferase (ATF2-luc) reporter

(21), which specifically monitors MuSK-dependent stimulation in transfected HEK293 cells. Overexpression of LRP4 and MuSK activated the ATF2-luc reporter in the absence of agrin, as previously reported (22). The EK mutant minimally and the RH mutant moderately impaired LRP4-induced activation of ATF2-luc (Fig. 3A). Addition of agrin to the medium markedly enhanced the ATF2-luc activity for the wild-type LRP4, whereas both mutants completely abolished responsiveness to agrin (Fig. 3A).

We also examined effects of the mutations on MuSK phosphorylation that occurs immediately after formation of the agrin/LRP4/MuSK complex. Consistent with its effects on the signaling activity, agrin enhanced MuSK phosphorylation in the presence of wild-type LRP4 but not in the presence of mutant LRP4 in HEK293 cells (Fig. 3B) and in Lrp4-downregulated C2C12 myoblasts (Fig. 4B). Similarly, wild-type LRP4, but not EK and RH mutants, rescued AChR clustering in Lrp4-downregulated C2C12 myotubes (Fig. 4C). These results support the notion that the EK and RH mutations compromise agrin-mediated activation of MuSK and AChR clustering.

LRP4 has also been known as an extracellular antagonist for Wnt signaling. Wnt signaling is involved in tissue development including limb, bone and kidney. Indeed, previously reported mutations of *LRP4* in human, mouse and cow exhibit structural abnormalities in limb, bone and/or kidney. We thus examined the effects of our LRP4 mutations on Wnt-signaling pathway using the TOPFLASH reporter. Wild-type LRP4 suppressed the Wnt3a-mediated TOPFLASH activity, and the EK and RH mutations retained similar suppressive effects (Fig. 3C). Lack of limb, bone and kidney symptoms in our patient can be attributed to EK and RH only affecting agrin-induced activation of MuSK but having no effect on Wnt signaling.

LRP4 directly binds to agrin and MuSK through its extracellular domain. To test the effects of the LRP4 mutations on binding to MuSK and agrin, we performed cell surface-binding assays. We first confirmed that the EK and RH mutants had no effect on LRP4 expressions in cell body and cell membrane in COS7 cells (Supplementary Material, Fig. S1). MuSKect-mycAP (Fig. 5A) and agrin-mycAP (Fig. 5B) bound efficiently to wild-type LRP4 expressed on the surface of COS7 cells. The RH and EK mutants compromised binding of both MuSKect-mycAP and agrin-mycAP (Fig. 5A and B). We also analyzed direct binding of LRP4ecd-Flag to purified MuSKect-mycAP (Fig. 5C) and agrin-mycAP (Fig. 5D) by *in vitro* plate-binding assays (Fig. 5E and F). We found that the mutations decreased binding affinities of LRP4 for agrin-mycAP (Fig. 5E) and MuSKect-mycAP (Fig. 5F). The RH mutant compromised binding of agrin and MuSK more than the EK mutant in the cell surface-binding assay but not in the *in vitro* plate-binding assay, which may be accounted for by some other molecules



B

4th YWTD motif in 3rd LDLR type B repeat

p.Glu1233Lys

Homo sapiens.tx	1205	LINNNL	GWPNGL	TVDKASSQL	LWADA	AH	TERIEA	AADL	NGANRHTL	VSPVQHPYGL	TLLDSY	1264	
Bos taurus.txt	1205	LINSNL	GWPNGL	TVDKASSQL	LWADA	AH	TERIEA	AADL	NGANRHTL	VSPVQHPYGL	TLLDAY	1264	
Canis familiaris	1321	LISNNL	GWPNGL	TVDKASSQL	LWADA	AH	TERIEA	AADL	NGGSRHTL	VSPVQHPYGL	TLLDSY	1380	
Rattus norvegicus	1205	LINNNL	GWPNGL	TVDKTSSSL	LWADA	AH	TERIEA	EADL	NGANRHTL	VSPVQHPYGL	TLLDSY	1264	
Mus musculus.tx	1205	LINNNL	GWPNGL	TVDKTSSSL	LWADA	AH	TERIEA	EADL	NGANRHTL	VSPVQHPYGL	TLLDSY	1264	
Gallus gallus.t	1249	LISNNL	GWPNGL	AVDKAGSQQ	LWADA	AH	TERIEA	AADL	NGANRRLL	VSPVQHPYGL	TLLDSY	1308	
Tetraodon nigro	1025	LISNNL	GWPNGL	AIDTAGSQQ	LWADA	AH	TERIEA	AADL	NGQRRRL	LVTPVQHPYGL	TLLGSH	1084	
Drosophila mela	1381	IVTANL	GWPNGL	SLDLKSKRI	IYWD	A	RLKTI	DSCDY	TGNQRKL	IMSSLHHPYAL	ALSDN	1440	
Aedes aegypti.t	1422	IVTTDL	GFVSL	AVDSVENRI	IYWD	S	KA	KRIE	SCDF	NGNSRKL	LLNNLSHPYAL	TVTST	1481

.....**.....*

5th YWTD motif in 3rd LDLR type B repeat

p.Arg1277His

Homo sapiens.tx	1265	IYWD	WQTRS	IHRADKGTGS	NVIL	VRSNLP	GLMDM	QAVDRAQP	--LGFN	KCGSR	NGGC	CSH	1322	
Bos taurus.txt	1265	IYWD	WQTRS	IHRADKGTGS	NVIL	VRSNLP	GLMDI	QAVDRSQP	--LGVN	KCGPR	NGGC	CSH	1322	
Canis familiaris	1381	IYWD	WQTRS	IHRADKGTGS	NVIL	VRSNLP	GLMDI	QAVDRAQP	--LGFN	KCGSR	NGGC	CSH	1438	
Rattus norvegicus	1265	IYWD	WQTRS	IHRADKSTGS	NVIL	VRSNLP	GLMDI	QAVDRAQP	--LGFN	KCGSR	NGGC	CSH	1322	
Mus musculus.tx	1265	IYWD	WQTRS	IHRADKSTGS	NVIL	VRSNLP	GLMDI	QAVDRAQP	--LGFN	KCGSR	NGGC	CSH	1322	
Gallus gallus.t	1309	IYWD	WQTRS	IHRADKDSGAN	IVL	VRANLP	GLMDI	QAVDRAQP	--LGFN	KCGVR	NGGC	CSH	1366	
Tetraodon nigro	1085	IYWD	WQTRS	IQRADKTTGT	NTI	TVRSNLP	GLMDI	QAVDMERP	--LGFN	KCGRR	NGGC	CSH	1142	
Drosophila mela	1441	IYWD	WQSKALH	MTEERRN	ISAKRDI	ITNIDGL	MDIKI	IYQNQ	QSTMK	NACGN	NNGC	CSH	1500	
Aedes aegypti.t	1482	IYWD	WVTKALHSV	SKLNTS	SKVRK	VAKDLE	ELMDV	KVVLP	GPSD	--SQDD	FCCG	NNGC	CSH	1539

*****.....**.....*

Figure 2. Structure and previously identified mutations of LRP4. (A) Domain structure of LRP4 and positions of reported mutations in human, mouse and cow. p.Glu1233Lys (EK mutation) and p.Arg1277His (RH mutation) in the current studies are shown in bold. In human, LRP4 mutations cause CLSS (MIM 212780) and sclerosteosis-2 (SOST2, MIM 614305). SNPs are also associated with an increased risk for Richter syndromes (RS) and a low-trauma fracture (LTF) due to decreased bone mineral density. In mouse, mutations cause abnormal development of the apical ectodermal ridge (AER) leading to polysyndactyly and tooth abnormality, as well as abnormal developments of limbs (LIMB) and the neuromuscular junctions (NMJ). In cow, mutations lead to mulefoot disease (MFD). LRP4 harbors eight low-density lipoprotein receptor (LDLR) domain class A, four epidermal growth factor-like domains, a calcium-binding EGF-like domain, four LDLR class B repeat (β -propeller domain), a transmembrane domain and an intracellular domain. The LDLR type B repeat contains five tandem repeats of an YWTD motif to build a propeller-like structure. NPSY close to the C-terminal end is a motif for endocytosis and ESQV at the C-terminal end is a motif for binding to PDZ-containing proteins. (B) Positions of the EK and RH mutations downstream of the 4th and 5th YWTD motifs (boxed). The amino acid sequences are highly conserved across vertebrates but not in insects. Asterisks indicate strictly conserved amino acids, and dots indicate loosely conserved amino acids.




Figure 3. p.Glu1233Lys (EK) and p.Arg1277His (RH) mutants compromise agrin-mediated upregulation of MuSK signaling but retain Wnt-suppressive activity in HEK293 cells. (A) ATF2-luciferase reporter assay of HEK293 cells to quantify agrin-mediated activation of the MuSK signaling pathway. Cells were transfected with ATF2-luc reporter and Renilla reporter plasmids along with MuSK cDNA and the indicated LRP4 cDNA. Cells were cultured with or without 10 ng/ μ l agrin. Wild-type (WT) LRP4-activated MuSK without agrin, and agrin further enhanced the activation. The EK and RH mutations compromise MuSK activation in the presence or absence of agrin. (B) MuSK phosphorylation assay of HEK293 cells transfected with Flag-MuSK and the indicated LRP4 cDNA with or without agrin (10 ng/ μ l). Phosphorylated MuSK was detected by immunoprecipitation of cell lysate by anti-phosphotyrosine antibody (p-Tyr) followed by immunoblotting with anti-FLAG antibody. Wild-type LRP4 phosphorylates MuSK, which is further enhanced by agrin, but EK and RH mutants abolish responsiveness to agrin. (C) TOPFLASH reporter assay of HEK293 cells to quantify responsiveness to Wnt3a. Cells were transfected with the TOPFLASH reporter and Renilla reporter plasmids along with the indicated LRP4 cDNA. Cells were cultured in the presence or absence of Wnt3a. Means and SD are indicated. Wild-type (WT) and mutant LRP4 (EK and RH) suppress the Wnt3a-mediated signaling to the same extent.

expressed on the cell surface, beneath the cell membrane or secreted from the cells.

Mutations in *LRP4* causing sclerosteosis-2 have No effect on MuSK signaling

In contrast to our EK and RH mutations in the 3rd β -propeller domain, p.Arg1170Trp (abbreviated as RW) and p.Trp1186Ser

(WS) mutations identified in a patient with sclerosteosis-2 impair Wnt-suppressing activity of LRP4 (12). We first confirmed that wild-type LRP4 and the two mutants are similarly expressed on the plasma membrane in HEK293 cells (Fig. 6A) as we observed in COS7 cells (Supplementary Material, Fig. S1). We then analyzed the effects of the two mutations on MuSK (Fig. 6B) and Wnt (Fig. 5C) signaling. Consistent with the previous report (12), the RW and WS mutations abrogated the Wnt-suppressing activity of LRP4 (Fig. 6C) but had no effect on agrin-induced MuSK signaling (Fig. 6B). Cell surface-binding assay also confirmed that the two mutants retained their ability to bind to agrin and MuSK (Fig. 6D).

As the four mutations affecting MuSK or Wnt signaling were all in the 3rd β -propeller domain, we scrutinized the positions of mutations by homology modeling of the 3rd β -propeller domain of human LRP4 using the 1st β -propeller domain of human LRP6 (PDB ID: 3SOV). The 3rd β -propeller domain contains six blade-like structures and displays a YWTD motif at the second β sheet below the surface of each blade (Fig. 7A and Supplementary Material, Movie S1). In this model, the EK and RH mutations, which only affect agrin/LRP4/MuSK signaling, are located on edge of the 5th and 6th blades, respectively (Fig. 7B and Supplementary Material, Movie S1). In contrast, the RW and WS mutations, which only affect Wnt signaling, are located in a central cavity of the propeller (Fig. 7C and Supplementary Material, Movie S1).

Artificially engineered Lrp4 mutations at the edge of the 3rd β -propeller domain affect MuSK signaling and those in the central cavity affect Wnt signaling

To further confirm that the edge of the 3rd β -propeller domain mediates MuSK signaling and that the central cavity mediates Wnt signaling, we introduced four other artificial mutations based on structural modeling of the 3rd β -propeller domain (Fig. 7A and Supplementary Material, Movie S1). As RH and EK mutations affected two exposed amino acids on the 2nd β sheet, we introduced an alanine into two neighboring amino acids to make IA and VA mutations (Fig. 7B and Supplementary Material, Movie S1). Similarly, as WS and RW mutations were facing the central cavity of the 3rd β -propeller domain, we introduced an alanine into the corresponding amino acids in the other blades to make YA and NA mutations (Fig. 7C and Supplementary Material, Movie S1). We then examined the effects of each mutation on MuSK and Wnt signaling. As expected, the VA and IA mutations at the edge of the 3rd β -propeller domain affected MuSK signaling (Fig. 8A), but not Wnt signaling (Fig. 8B). In contrast, the NA and YA mutations in the central cavity normally activated MuSK signaling (Fig. 8A), but lost Wnt-suppressive activity (Fig. 8B). Similarly, the cell surface-binding assay showed that the VA and IA mutations reduced binding of agrin and MuSK (Fig. 8C and D). Thus, the artificial mutations further underscore the differential signaling roles of the edge and the central cavity of the 3rd β -propeller domain.

DISCUSSION

LRP4 mutations cause a novel CMS

Because mutations in *AGRN* (25) and *MUSK* (26) have been known to cause CMS and because LRP4 was shown to be a




Figure 4. p.Glu1233Lys (EK) and p.Arg1277His (RH) mutants compromise agrin-mediated upregulation of MuSK signaling and AChR clustering in C2C12 myoblasts/myotubes. (A) Endogenous *Lrp4* expression in C2C12 myoblasts is suppressed by shRNA against mouse *Lrp4* (shLrp4) by qRT-PCR. (B) MuSK phosphorylation assay of differentiation-induced C2C12 myoblasts transfected with shControl or shLrp4 and the indicated *LRP4* cDNA. Phosphorylated MuSK was detected by immunoprecipitation of cell lysate by anti-phosphotyrosine antibody (p-Tyr) followed by immunoblotting with anti-MuSK antibody. Wild-type LRP4, but not EK and RH mutants, phosphorylates MuSK in *Lrp4*-deficient myoblasts. (C) Agrin-mediated AChR clustering in C2C12 myotubes. Myotubes are transfected with EGFP cDNA, shLRP4 and the indicated *LRP4* cDNA using electroporation. AChR is visualized with Alexa594-conjugated α -bungarotoxin at 12 h after adding 10 ng/ml agrin. Right panels: Morphometric analysis showing that wild-type (WT) LRP4, but not EK and RH mutants, rescues the number and the length of AChR clusters in *Lrp4*-downregulated C2C12 myotubes. LRP4 has no effect on myotube length.

coreceptor for agrin that mediates activation of MuSK (Fig. 7D) (2,3). *LRP4* has been a candidate gene for a CMS for a number of years. In this communication, we show that mutations in *LRP4* cause a CMS and that the identified mutations affect MuSK signaling by compromising binding of LRP4 to both agrin and MuSK.

Our data predict that the identified *LRP4* mutations interfere with agrin-LRP4-MuSK signaling and thereby hinder concentration of AChR on the junctional folds as well as normal development and maintenance of the entire junction. Our EP studies show that the synaptic contacts are dysplastic (Fig. 1) and that the nerve terminal and postsynaptic areas at the EP regions are hypoplastic (Table 1), but the AChR content of EPs and the synaptic response to ACh are not appreciably reduced. Because the patient has a myasthenic disorders by clinical and EMG criteria, we attribute sparing of the intercostal muscles to different expressivity of the genetic defect in different muscles. Sparing of selected muscles can occur in both autoimmune and congenital myasthenias and is indicated by absence of muscle weakness or a decremental EMG response from some muscles in either disorder. For example, in MuSK antibody-positive myasthenia, EPs in intercostal and biceps brachii muscles have a normal AChR content, generate normal MEPP amplitudes, and have well preserved junctional folds (27,28). Analysis of *Musk* and *Lrp4* expressions in mouse muscles by quantitative RT-PCR revealed that expressions of

Musk in omohyoid and trapezius muscles were less than those in the other muscles (Supplementary Material, Fig. S2). The least expression of *Musk* in mouse omohyoid has been recently reported (29). In contrast, *Musk* expression in intercostal muscle was ~three times more compared with omohyoid. Although human specimens of various muscles were not available for our studies, high and low MuSK expressions in intercostal and trapezius muscles may partly account for spared and impaired NMJ signal transmissions in intercostal and trapezius muscles, respectively, in our patient with *LRP4* mutations.

Position-specific disease phenotypes of *LRP4* mutations

The extracellular domain of LRP4 is known to bind to several proteins: agrin (2,3), MuSK (4), Wnt ligands (30), dkk1 (31), a Wnt inhibitor (32,33), sclerostin (31), another Wnt inhibitor (32,33) and possibly apoE (34). Specific binding domains of LRP4 have been dissected: agrin binds to the LDLa repeats 6–8, EGF-like domains, and the 1st β -propeller domain (Fig. 7B and Supplementary Material, Movie S1) (4,23); MuSK binds to the 4th/5th LDLa repeats and the 3rd β -propeller domain (4); sclerostin binds to the 3rd β -propeller domain (12); and apoE binds to LDLa (34). As for Wnt ligands, the precise molecular mechanisms how LRP4 suppresses Wnt signaling remain elusive, although the Wnt-suppressive effect of LRP4 is well established (35).




Figure 5. The p.Glu1233Lys (EK) and p.Arg1277His (RH) mutants impair binding of LRP4 to MuSK and agrin. (A and B) Cell surface-binding assays. COS7 cells were transfected with the wild-type or mutant *LRP4* cDNA and added with concentrated conditioned medium containing either neural Agrin-mycAP or MuSKect-mycAP as indicated. Bound MuSKect-mycAP or agrin-mycAP was stained for the alkaline phosphatase activity (A). (B) The mean and SD of ALP activities of bound agrin-mycAP and MuSKect-mycAP in three independent wells. The RH and EK mutants reduce binding of MuSKect-mycAP and agrin-mycAP. (C and D) Western blotting with an anti-Flag antibody for detecting LRP4ecd-Flag; and anti-myc antibody for agrin-myc and MuSK-myc. All the transfected cDNAs were similarly expressed. (E and F) *In vitro* plate-binding assays. Plates were coated with the wild-type or mutant LRP4ecd-Flag protein and overlaid with purified agrin-mycAP protein (E) and MuSKect-mycAP (F). The EK and RH mutants reduce binding affinities for MuSKect-mycAP and agrin-mycAP. Mean and SE are plotted ($n = 4$; $P < 0.05$ for both MuSKect-mycAP and agrin-mycAP by two-way ANOVA).




Figure 6. The p.Arg1170Trp (RW) and p.Trp1186Ser (WS) mutants retain the activity of agrin-mediated upregulation of MuSK signaling but compromise Wnt-suppressive activity. (A) Western blotting with an anti-Flag antibody for detecting full-length LRP4-Flag. Membrane proteins are biotinylated and precipitated with streptavidin. β -Actin proteins in each sample were detected as loading control. (B and C) ATF2-luciferase (B) and TPOFLASH (C) reporter assays of HEK293 cells to quantify activation of MuSK and Wnt signaling pathways, respectively. The RH mutant is included as a control. Means and SD of three independent experiments are indicated. (D) Cell surface-binding assays as in Figs 5A and B. Both the RW and WS mutants are able to bind to agrin-mycAP (upper) and MuSKect-mycAP (lower).

The diverse array of binding partners enables LRP4 to play an essential role in multiple biological processes including limb and kidney morphogenesis (16,31); bone development through cell fate decision and migration (35); and synaptogenesis (6,34). The multiple phenotypes caused by mutations in the 3rd β -propeller domain prompted us to scrutinize different regions of this domain, and we found that the edge mediates MuSK signaling and the central cavity mediates Wnt signaling. That a single missense mutation in the 3rd β -propeller domain compromises LRP4 binding to MuSK supports a previous observation that MuSK is bound to the 3rd β -propeller domain of LRP4 (Fig. 7B and Supplementary Material, Movie S1) (4). In contrast, reduced binding of our LRP4 mutants to agrin was unexpected because agrin binds to the EGF-like domain, LDLA repeats 6–8 and the 1st β -propeller domain (4,23). The 2nd and 3rd β -propeller domains, however, enhance binding to agrin to ~170% of the truncated LRP4 lacking these domains (4). Accordingly, mutations in the 3rd β -propeller domain in our patient are likely to compromise the enhancing effect conferred by the 3rd β -propeller domain of LRP4.

MATERIALS AND METHODS

Patient

All human studies were in accord with and approved by the Institutional Review Boards of the Mayo Clinic and Nagoya University

Graduate School of Medicine. The patient's father gave informed consent for the patient to participate in the study. Venous blood sample was obtained from the patient and his father and genomic DNA was isolated with the QIAamp Blood DNA kit (Qiagen) according to the manufacturer's recommendations.

Neuromuscular junction studies

Intercostal muscle specimens were obtained from the patient and from control subjects without muscle disease undergoing thoracic surgery. Cryosections were used to colocalize the acetylcholine receptor (AChR) and acetylcholine esterase (AChE) as described (36). AChE was also visualized on teased, glutaraldehyde-fixed muscle fibers cytochemically (37). EPs were localized for electron microscopy (38) and quantitatively analyzed (39) by established methods. Peroxidase-labeled α -bgt was used for the ultrastructural localization of AChR (40). The number of AChRs per EP was measured with [125 I] α -bgt. The amplitude of the miniature EP potential (MEPP) and EP potential (EPP) amplitudes and estimates of the quantal content of the EPP (m) were measured as previously described (41,42). Single-channel patch-clamp recordings were performed as previously described (43,44).

Exome-capture resequencing analysis

We enriched exonic fragments using the SureSelect human all exon v2 (Agilent Technologies) and sequenced 50 bp of each




Figure 7. The 3rd β -propeller domain of LRP4 and scheme of agrin/LRP4/MuSK complex. (A–C) Simulated three-dimensional structure of the 3rd β -propeller domain of LRP4. Positions of the analyzed mutations are indicated. The RH and EK mutations (red) are identified in our CMS patient. The RW and WS mutations (yellow) are reported in sclerosteosis-2 (12). Amino acids that are artificially mutated to alanine are shown in purple or green. Mutations at the edge of the β -propeller domain and in the central cavity are grouped together by boxes. The edge (B) and central cavity (C) of the 3rd β -propeller domain are enlarged to show locations of the naturally occurring and artificially introduced mutations. The viewing positions of (B) and (C) are not identical to (A). (D) Scheme of agrin/LRP4/MuSK. Arrows represent direct interactions: Agrin binds to the 1st EGF-like domain and the 1st β -propeller domain of LRP4 (23); MuSK binds to the 4th/5th LDLA repeats and the 3rd β -propeller domain of LRP4 (4). An artificial missense mutation in the 1st IgG-like domain of MuSK impairs binding to LRP4 (4) and deletion of this domain abolishes agrin-mediated AChR clustering (24), but the exact LRP4-binding domain(s) of MuSK remain elusive. We propose that the edge of the 3rd β -propeller domain of LRP4 is essential for binding to MuSK and for signal transduction at NMJ.

fragment in a single direction using ABI SOLiD4 system (Life Technologies). The sequencing fragments were mapped to the human genome hg19/GRCh37 using BioScope 1.4 (Life Technologies). SNVs/indels were called by Avadis NGS 1.3.1 (Agilent) using default parameters. We restricted our analysis to 34 candidate genes that were known to be essential for neuromuscular signal transmission: *ABL2*, *ACHE*, *AGRN*, *APP*, *CHAT*, *CHRNA1*, *CHRN1*, *CHRND*, *CHRNE*, *CHRNA1*, *COLQ*, *CSNK2B*, *DAG1*, *DOK7*, *DTNA*, *DVL1*, *ETV5*, *GFPT1*, *LAMB2*, *LRP4*, *MUSK*, *NRG1*, *NTF4*, *PAK1*, *PGGT1B*, *PHLDB2*, *PLEC*, *RAPSN*, *SCN4A*, *SLC18A3*, *SNTB2*, *STNA1* and *SYNC*.

Primer pairs for each exon and the flanking intron regions of *LRP4* were designed with Primer 3. PCR products were directly sequenced with ABI PRISM 3730 DNA Analyzer and BigDye Terminator Cycle Sequencing Kit version 1.1 according to the manufacturer's protocols (Applied Biosystems).

Plasmids

Full-length human *LRP4* cDNA (Open Biosystems) was cloned into the *EcoRI* site of the pcDNA3.1 mammalian expression vector. The extracellular domain (amino acid 1–1722) of




Figure 8. Artificially engineered p.Val1252Ala (VA) and p.Ile1287Ala (IA) compromise agrin-mediated upregulation of MuSK signaling, whereas p.Asn1214Ala (NA) and p.Tyr1256Ala (YA) compromise Wnt-suppressive activity. (A) ATF2-luciferase reporter assay of HEK293 cells as in Figs 3A and 6B. The IA and VA mutations are at the edge, whereas the YA and NA mutations are in the central cavity (see Fig. 7A and Supplementary Material, Movie S1). The RH mutation in our CMS patient is included as a control. (B) TOPFLASH reporter assay of HEK293 cells as in Figs 3C and 6C. (C and D) Cell surface-binding assays as in Figs 5A, B, and 6D. The ALP activities of bound agrin-mycAP and MuSKect-mycAP in three independent wells are shown in (C). Mean and SD are indicated in (A)–(C).

human *LRP4* cDNA was cloned into the *HindIII* and *XbaI* sites upstream of a 3xFlag epitope of a mammalian expression vector p3xFlag-CMV-14 to generate hLRP4ecd-Flag for the plate-binding assay. The mouse *Musk* cDNA in pExpress-1 was purchased from Open Biosystems and was used for the luciferase assay in HEK293 cells. Human *MUSK* cDNA with a Flag-tag at the N-terminal end was cloned into the *EcoRI* and *XbaI* sites of the p3xFlag-CMV-14 to generate Flag-MuSK, and was used for the co-immunoprecipitation assay. For vector expressing shRNA against Lrp4, double-stranded oligonucleotides (sense, 5'-GATCCCGGAAGTTTCTGACATAAAATTCAAGAGATTTATGTCAGGAACTTCCTTTTGGAAA-3' and 5'-AGCTTTTCCAAAAGGAAGTTTCTGACATAAAATCTCTTGAA TTTATGTCAGGAACTTCCTGG-3') were cloned into a lentiviral vector pLenti-CMV-GFPx2-DEST, which was kindly provided by Dr Eric Campeau at the University of Massachusetts Medical School. The extracellular domain of mouse *Musk* cDNA fused to a myc-tag and alkaline phosphatase (MuSKect-mycAP) was kindly provided by Dr Lin Mei. To generate rat agrin-mycAP that retains potency to facilitate AChR clustering as a neural agrin, we cloned amino acid 1141–1937 of rat *Agrn* cDNA (M64780.1) into pAptag-5 (GenHunter) at the *HindIII* and *SnaBI* sites, so that the Igk-originated signal peptide is attached upstream of the insert and the myc-tag/alkaline phosphatase downstream. Mutant *LRP4* plasmids carrying p.Arg1170Trp, p.Trp1186Ser, p.Asn1214Ala, p.Glu1233Lys, p.Val1252Ala, p.Tyr1256Ala, p.Arg1277His and p.Ile1287Ala were generated by the QuikChange Site-Directed Mutagenesis kit (Stratagene). Lack of PCR artifacts was verified by sequencing the entire inserts. Super 8x TOPFLASH plasmid (Addgene), ATF2-Luc (21) and phRL-TK Renilla luciferase vector (Promega) were used for the luciferase reporter assay.

Cell cultures

HEK293, L, COS and C2C12 cells were cultured in the Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and transfected with FuGENE 6 transfection reagent (Roche). L cells stably expressing Wnt3a were purchased from ATCC. Conditioned media were prepared by culturing Wnt3a-producing and control L cells for 4 days. The LRP4ecd-Flag, agrin-mycAP and MuSKect-mycAP proteins were produced by transfecting each plasmid into HEK293 cells in serum-free DMEM. Recombinant rat C-terminal agrin (10 ng/ml, R&D systems) was used for agrin treatment except for the binding assays. For AChR clustering assay, C2C12 myoblast were seeded on a plate coated with collagen I (BD Biosciences) and differentiated in DMEM supplemented with 2% horse serum for 5 days. The differentiated myotubes were electroporated with shLrp4 and each *LRP4* cDNA construct using the NEPA21 electroporator and the CUY900-13-3-5 electrode for attached cells (NepaGene), and then treated with 2 µg/ml doxycycline for 2 days to induce shRNA expression. Cells were treated with 10 ng/ml agrin to induce AChR clusters for 12 h. Cells were stained with 10 mg/ml Alexa594-conjugated α-bungarotoxin (1:100, Invitrogen) to label AChR and fixed in 2% paraformaldehyde. Fluorescence images were observed under an Olympus XL71 fluorescence microscope and analyzed with MetaMorph software (Molecular Devices). The lengths of

AChR clusters and myotubes were defined as the longest axes of Alexa594 signals and GFP signals, respectively, in the transfected cells. AChR clusters with the axis length <4 µm were excluded from the analysis.

Luciferase assays

HEK293 cells were transfected with ATF2-Luc and phRL-TK along with the *MUSK* and *LRP4* cDNAs. Cells were cultured for 24 h in the presence or absence of agrin in the medium in a 96-well plate. Cells were lysed with the passive lysis buffer (Promega) and assayed for the luciferase activity using the Dual luciferase system (Promega). Each experiment was done in triplicate.

Biotinylation of LRP4 on plasma membrane and western blotting

HEK293 cells transfected with MuSK and *LRP4* plasmids in the presence of agrin were cultured for 24 h. C2C12 myoblasts transfected with shLrp4 and human *LRP4* cDNA using NEPA21 electroporator and electroporation cuvettes (NepaGene) were cultured in a differentiation medium for 2 days in the presence of 2 µg/ml doxycycline and 10 ng/ml agrin. Efficient downregulation of Lrp4 was confirmed by quantitative RT-PCR. Cells were lysed with a buffer containing 50 mM HEPES pH 7.0, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl₂, 1 mM EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 1 µg/µl aprotinin, 1 µg/µl leupeptin, 1 µg/µl pepstatin A, 1 mM PMSF, 1 mM sodium orthovanadate. Cell lysates were subjected to coimmunoprecipitation using 1 µg of anti-phosphotyrosine antibody (4G10, Upstate) attached to protein G Sepharose beads (GE Healthcare). For biotinylation of LRP4 on plasma membrane, LRP4-transfected HEK293 cells were washed twice with PBS containing 1 mM MgCl₂ and 0.1 mM CaCl₂ (PBS/CM), followed by incubation with 0.5 mg/ml sulfo-NHS-SS-biotin (Pierce) in PBS/CM at room temperature for 30 min. The cells were then washed once with PBS/CM and incubated with 10 mM monoethanolamine for quenching free biotin. The cells were harvested with RIPA buffer (Pierce) after several washing with ice-cold PBS and the cell lysates were incubated with streptavidin sepharose beads (GE healthcare) to purify cell membrane protein. Total or precipitated proteins were dissolved in 1 × Laemmli buffer, separated on a 10 or 7.5% SDS-polyacrylamide gel and transferred to a polyvinylidene fluoride membrane (Immobilon-P, Millipore). Membranes were washed in Tris-buffered saline containing 0.05% Tween 20 (TBS-T) and blocked for 1 h at room temperature in TBS-T with 3% bovine serum albumin. The membranes were incubated overnight at 4°C either with the mouse monoclonal anti-Myc 9E10 (dilution 1:500, sc-40, Santa Cruz Biotechnology), anti-Flag M2 (dilution 1:4000, F1804, Sigma-Aldrich), anti-LRP4 (dilution 1:1000, ab85697, Abcam), anti-MuSK (1:500, sc-6009, Santa Cruz Biotechnology) or anti-β-actin (dilution 1:200, sc-47778, Santa Cruz Biotechnology) antibody. The membranes were washed three times for 10 min with TBS-T and incubated with secondary goat anti-mouse IgG antibody conjugated to horseradish peroxidase (HRP) (1:6000, LNA931 V/AG, GE Healthcare) for 1 h at room temperature. The blots were detected with Amersham ECL western blotting detection reagents (GE Healthcare) and quantified with the ImageJ program.

Preparation of agrin-MycAP, MuSKect-MycAP and LRP4ecd-flag proteins

Agrin-mycAP and MuSKect-mycAP in the conditioned media of transfected HEK293 cells were concentrated ~100-fold using Amicon Ultra-4 filters (Millipore). For the cell surface-binding assay, we used the concentrated conditioned media. For the plate-binding assay, we further purified agrin-mycAP and MuSKect-mycAP using the c-myc-Tagged Protein Mild Purification Kit ver. 2 (MBL). Wild-type and mutant hLRP4ecd-Flag proteins were purified with the Anti-DYKDDDDK-tag Antibody Beads (Wako) from the conditioned medium of the transfected HEK293. Purified MuSKect-mycAP and hLRP4ecd-Flag were detected by anti-myc antibody (9E10, Abcam) or anti-Flag antibody (M2, Sigma-Aldrich), respectively. We also measured concentrations of each protein by SDS-PAGE followed by protein staining with SYBRO Ruby Protein Gel Stain (Molecular Probes) using BSA as a standard.

Cell surface- and plate-binding assays

For the cell surface-binding assay, COS cells were transfected with LRP4 using FuGENE 6 (Roche). Cells were incubated 24 h with concentrated conditioned medium containing either agrin-mycAP or MuSKect-mycAP for 1.5 h at RT. Cells were washed with HABH buffer (0.5 mg/ml bovine serum albumin, 0.1% NaN₃ and 20 mM HEPES, pH 7.0, in Hank's balanced salt solution), fixed in 60% acetone for 10 min on ice followed by 4% paraformaldehyde in 20 mM HEPES (pH 7.0) in Hank's balanced salt solution for 10 min on ice. Fixed cells were washed once with 20 mM HEPES (pH 7.0) and 150 mM NaCl, incubated at 65°C for 30 min, washed with 0.1 M Tris-HCl (pH 8.0), washed with water and stained with NBP/BCIP solution (Roche). For plate-binding assay, the Immuno plate (Nunc) was coated with 0.15 µg of purified wild-type or mutant LRP4ecd-Flag at 4°C overnight and then incubated with a blocking buffer (1%BSA in PBS) at RT for 1 h. For the binding assays, 80 µl of serially diluted agrin-mycAP or MuSKect-mycAP were added to wells that were coated with wild-type or mutant LRP4ecd-Flag in a blocking buffer. The reagents were incubated for 2 h at RT, and then washed twice with PBS. Bound AP activity was measured using LabAssay ALP (Wako).

Homology modeling

The primary sequence of the 3rd β-propeller domain of hLRP4 (accession number: AAI36669, amino acid 1048–1350) and the coordinates of crystal structure of the 1st β-propeller domain (amino acid 20–326) of human LRP6 (PDB ID: 3SOV) were loaded into the Molecular Operating Environment software (MOE, Chemical Computing Group). The primary structures of each β-propeller domain of hLRP4 and hLRP6 were sequence-aligned and manually corrected by the structure-alignment method. Molecular mechanics were calculated by an MMFF94x force field.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at *HMG* online.

ACKNOWLEDGEMENTS

We thank Keiko Itano for expert technical assistance.

Conflict of Interest statement. None declared.

FUNDING

This work was supported by Grants-in-Aid from the MEXT and MHLW of Japan to B.O., M.I., A.M. and K.O.; and by NIH Research Grant NS6277 from the NINDS and by Research Grant from the MDA to A.G.E.

REFERENCES

- Engel, A.G. (2012) Current status of the congenital myasthenic syndromes. *Neuromuscul. Disord.*, **22**, 99–111.
- Kim, N., Stiegler, A.L., Cameron, T.O., Hallock, P.T., Gomez, A.M., Huang, J.H., Hubbard, S.R., Dustin, M.L. and Burden, S.J. (2008) Lrp4 is a receptor for agrin and forms a complex with MuSK. *Cell*, **135**, 334–342.
- Zhang, B., Luo, S., Wang, Q., Suzuki, T., Xiong, W.C. and Mei, L. (2008) LRP4 serves as a coreceptor of agrin. *Neuron*, **60**, 285–297.
- Zhang, W., Coldefy, A.S., Hubbard, S.R. and Burden, S.J. (2011) Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK). *J. Biol. Chem.*, **286**, 40624–40630.
- Wu, H., Xiong, W.C. and Mei, L. (2010) To build a synapse: signaling pathways in neuromuscular junction assembly. *Development*, **137**, 1017–1033.
- Yumoto, N., Kim, N. and Burden, S.J. (2012) Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. *Nature*, **489**, 438–442.
- Wu, H., Lu, Y., Shen, C., Patel, N., Gan, L., Xiong, W.C. and Mei, L. (2012) Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation. *Neuron*, **75**, 94–107.
- Higuchi, O., Hamuro, J., Motomura, M. and Yamanashi, Y. (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. *Ann. Neurol.*, **69**, 418–422.
- Zhang, B., Tzartos, J.S., Belimezi, M., Ragheb, S., Bealmear, B., Lewis, R.A., Xiong, W.C., Lisak, R.P., Tzartos, S.J. and Mei, L. (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. *Arch. Neurol.*, **69**, 445–451.
- Pevzner, A., Schoser, B., Peters, K., Cosma, N.C., Karakatsani, A., Schalke, B., Melms, A. and Kroger, S. (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. *J. Neurol.*, **259**, 427–435.
- Li, Y., Pawlik, B., Elcioglu, N., Aglan, M., Kayserili, H., Yigit, G., Percin, F., Goodman, F., Nurnberg, G., Cenani, A. *et al.* (2010) LRP4 mutations alter Wnt/β-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome. *Am. J. Hum. Genet.*, **86**, 696–706.
- Leupin, O., PETERS, E., Halleux, C., Hu, S., Kramer, I., Morvan, F., Bouwmeester, T., Schirle, M., Bueno-Lozano, M., Fuentes, F.J. *et al.* (2011) Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. *J. Biol. Chem.*, **286**, 19489–19500.
- Styrkarsdottir, U., Halldorsson, B.V., Gretarsdottir, S., Gudbjartsson, D.F., Walters, G.B., Ingvarsson, T., Jonsdottir, T., Saemundsdottir, J., Snorraddottir, S., Center, J.R. *et al.* (2009) New sequence variants associated with bone mineral density. *Nat. Genet.*, **41**, 15–17.
- Choi, H.Y., Dieckmann, M., Herz, J. and Niemeier, A. (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. *PLoS ONE*, **4**, e7930.
- Johnson, E.B., Steffen, D.J., Lynch, K.W. and Herz, J. (2006) Defective splicing of *Megf7/Lrp4*, a regulator of distal limb development, in autosomal recessive mulefoot disease. *Genomics*, **88**, 600–609.
- Johnson, E.B., Hammer, R.E. and Herz, J. (2005) Abnormal development of the apical ectodermal ridge and polysyndactyly in *Megf7*-deficient mice. *Hum. Mol. Genet.*, **14**, 3523–3538.
- Rasi, S., Spina, V., Brusca, A., Vaisitti, T., Tripodo, C., Forconi, F., De Paoli, L., Fangazio, M., Sozzi, E., Cencini, E. *et al.* (2011) A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. *Br. J. Haematol.*, **152**, 284–294.

18. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S. and Sunyaev, S.R. (2010) A method and server for predicting damaging missense mutations. *Nat. Methods*, **7**, 248–249.
19. Kumar, P., Henikoff, S. and Ng, P.C. (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat. Protoc.*, **4**, 1073–1081.
20. Schwarz, J.M., Rodelsperger, C., Schuelke, M. and Seelow, D. (2010) MutationTaster evaluates disease-causing potential of sequence alterations. *Nat. Methods*, **7**, 575–576.
21. Ohkawara, B. and Niehrs, C. (2011) An ATF2-based luciferase reporter to monitor non-canonical Wnt signaling in *Xenopus* embryos. *Dev. Dyn.*, **240**, 188–194.
22. Okada, K., Inoue, A., Okada, M., Murata, Y., Kakuta, S., Jigami, T., Kubo, S., Shiraishi, H., Eguchi, K., Motomura, M. *et al.* (2006) The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. *Science*, **312**, 1802–1805.
23. Zong, Y., Zhang, B., Gu, S., Lee, K., Zhou, J., Yao, G., Figueiredo, D., Perry, K., Mei, L. and Jin, R. (2012) Structural basis of agrin-LRP4-MuSK signaling. *Genes. Dev.*, **26**, 247–258.
24. Zhou, H., Glass, D.J., Yancopoulos, G.D. and Sanes, J.R. (1999) Distinct domains of MuSK mediate its abilities to induce and to associate with postsynaptic specializations. *J. Cell Biol.*, **146**, 1133–1146.
25. Huze, C., Bauche, S., Richard, P., Chevessier, F., Goillot, E., Gaudon, K., Ben Ammar, A., Chaboud, A., Grosjean, I., Lecuyer, H.A. *et al.* (2009) Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. *Am. J. Hum. Genet.*, **85**, 155–167.
26. Chevessier, F., Faraut, B., Ravel-Chapuis, A., Richard, P., Gaudon, K., Bauche, S., Prioleau, C., Herbst, R., Goillot, E., loos, C. *et al.* (2004) MUSK, a new target for mutations causing congenital myasthenic syndrome. *Hum. Mol. Genet.*, **13**, 3229–3240.
27. Selcen, D., Fukuda, T., Shen, X.-M. and Engel, A.G. (2004) Are MuSK antibodies the primary cause of myasthenic symptoms? *Neurology*, **62**, 1945–1950.
28. Shiraishi, H., Motomura, M., Yoshimura, T., Fukudome, T., Fukuda, T., Nakao, Y., Tsujihata, M., Vincent, A. and Eguchi, K. (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. *Ann. Neurol.*, **57**, 289–293.
29. Punga, A.R., Maj, M., Lin, S., Meinen, S. and Ruegg, M.A. (2011) MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity. *Eur. J. Neurosci.*, **33**, 890–898.
30. Bao, J., Zheng, J.J. and Wu, D. (2012) The structural basis of DKK-mediated inhibition of Wnt/LRP signaling. *Sci. Signal*, **5**, pe22.
31. Karner, C.M., Dietrich, M.F., Johnson, E.B., Kappesser, N., Tennert, C., Percin, F., Wollnik, B., Carroll, T.J. and Herz, J. (2010) Lrp4 regulates initiation of ureteric budding and is crucial for kidney formation—a mouse model for Cenani-Lenz syndrome. *PLoS ONE*, **5**, e10418.
32. Gilinka, A., Wu, W., Delius, H., Monaghan, A.P., Blumenstock, C. and Niehrs, C. (1998) Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. *Nature*, **391**, 357–362.
33. Semenov, M., Tamai, K. and He, X. (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. *J. Biol. Chem.*, **280**, 26770–26775.
34. Lu, Y., Tian, Q.B., Endo, S. and Suzuki, T. (2007) A role for LRP4 in neuronal cell viability is related to apoE-binding. *Brain Res.*, **1177**, 19–28.
35. Ohazama, A., Johnson, E.B., Ota, M.S., Choi, H.Y., Pomtaveetus, T., Oommen, S., Itoh, N., Eto, K., Gritli-Linde, A., Herz, J. *et al.* (2008) Lrp4 modulates extracellular integration of cell signaling pathways in development. *PLoS ONE*, **3**, e4092.
36. Fambrough, D.M., Engel, A.G. and Rosenberry, T.L. (1982) Acetylcholinesterase of human erythrocytes and neuromuscular junctions: homologies revealed by monoclonal antibodies. *Proc. Natl. Acad. Sci. USA*, **79**, 1078–1082.
37. Gautron, J. (1974) Cytochimie ultrastructurale des acétylcholinestérases. *Microscopie*, **21**, 259–264.
38. Engel, A.G. (2004) In Engel, A.G. and Franzini-Armstrong, C. (eds.), *Myology*. 3rd edn. McGraw Hill, New York, Vol. I, pp. 681–690.
39. Engel, A.G. (1994) In Engel, A.G. and Franzini-Armstrong, C. (eds.), *Myology*. 2nd edn. McGraw-Hill, New York, Vol. 2, pp. 1018–1045.
40. Engel, A.G., Lindstrom, J.M., Lambert, E.H. and Lennon, V.A. (1977) Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. *Neurology*, **27**, 307–315.
41. Engel, A.G., Nagel, A., Walls, T.J., Harper, C.M. and Waisburg, H.A. (1993) Congenital myasthenic syndromes: I. Deficiency and short open-time of the acetylcholine receptor. *Muscle Nerve*, **16**, 1284–1292.
42. Uchitel, O., Engel, A.G., Walls, T.J., Nagel, A., Atassi, M.Z. and Brill, V. (1993) Congenital myasthenic syndromes: II. Syndrome attributed to abnormal interaction of acetylcholine with its receptor. *Muscle Nerve*, **16**, 1293–1301.
43. Milone, M., Hutchinson, D.O. and Engel, A.G. (1994) Patch-clamp analysis of the properties of acetylcholine receptor channels at the normal human endplate. *Muscle Nerve*, **17**, 1364–1369.
44. Shen, X.M., Brengman, J.M., Sine, S.M. and Engel, A.G. (2012) Myasthenic syndrome AChRalpha C-loop mutant disrupts initiation of channel gating. *J. Clin. Invest.*, **122**, 2613–2621.

Verapamil Protects against Cartilage Degradation in Osteoarthritis by Inhibiting Wnt/ β -Catenin Signaling

Akira Takamatsu^{1,2}, Bisei Ohkawara¹, Mikako Ito¹, Akio Masuda¹, Tadahiro Sakai², Naoki Ishiguro², Kinji Ohno^{1*}

¹ Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan, ² Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

Abstract

In past years, the canonical Wnt/ β -catenin signaling pathway has emerged as a critical regulator of cartilage development and homeostasis. FRZB, a soluble antagonist of Wnt signaling, has been studied in osteoarthritis (OA) animal models and OA patients as a modulator of Wnt signaling. We screened for FDA-approved drugs that induce FRZB expression and suppress Wnt/ β -catenin signaling. We found that verapamil, a widely prescribed L-type calcium channel blocker, elevated FRZB expression and suppressed Wnt/ β -catenin signaling in human OA chondrocytes. Expression and nuclear translocation of β -catenin was attenuated by verapamil in OA chondrocytes. Lack of the verapamil effects in LiCl-treated and FRZB-downregulated OA chondrocytes also suggested that verapamil suppressed Wnt signaling by inducing FRZB. Verapamil enhanced gene expressions of chondrogenic markers of ACAN encoding aggrecan, COL2A1 encoding collagen type II α 1, and SOX9, and suppressed Wnt-responsive AXIN2 and MMP3 in human OA chondrocytes. Verapamil ameliorated Wnt3A-induced proteoglycan loss in chondrogenically differentiated ATDC5 cells. Verapamil inhibited hypertrophic differentiation of chondrocytes in the explant culture of mouse tibiae. Intraarticular injection of verapamil inhibited OA progression as well as nuclear localizations of β -catenin in a rat OA model. We propose that verapamil holds promise as a potent therapeutic agent for OA by upregulating FRZB and subsequently downregulating Wnt/ β -catenin signaling.

Citation: Takamatsu A, Ohkawara B, Ito M, Masuda A, Sakai T, et al. (2014) Verapamil Protects against Cartilage Degradation in Osteoarthritis by Inhibiting Wnt/ β -Catenin Signaling. PLoS ONE 9(3): e92699. doi:10.1371/journal.pone.0092699

Editor: Chunming Liu, University of Kentucky, United States of America

Received: October 2, 2013; **Accepted:** February 25, 2014; **Published:** March 21, 2014

Copyright: © 2014 Takamatsu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), the Ministry of Health, Labor and Welfare (MHLW) of Japan, and the Hori Sciences & Arts foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: ohnok@med.nagoya-u.ac.jp

Introduction

Osteoarthritis (OA) is a progressively degenerative joint disorder characterized by degradation of extracellular matrix (ECM) molecules, loss of articular cartilages, and formation of osteophytes. OA causes chronic disability in elderly people and is one of the major health problems worldwide [1]. No rational medical therapy is currently available for OA except for palliative pain control and physiotherapy, before patients require prosthetic joint replacement therapy.

In OA, dysfunction of articular chondrocytes compromises synthesis of ECM and enhances degradation of ECM, which leads to loss of ECM and cartilage degradation. Aggrecan (ACAN) is the most prominent proteoglycan in cartilage, which holds a large amount of water and ions, and confers mechanical elasticity. Collagens, and in particular collagen II, constitute a highly structured fibrillar network that holds spatial arrangement of tissue and provides tensile strength. ECM including ACAN and collagens are degraded by matrix metalloproteinases (MMPs), aggrecanases (ADAMTSs), and other matrix proteases [2,3]. Chondrocytes orchestrate fine-tuned gene expressions of ECM molecules and their catabolic enzymes to achieve tolerance to mechanical stress as well as elasticity of articular cartilages, which is compromised in OA.

Recent studies revealed that bone morphogenetic proteins (BMPs) [4], Indian hedgehog (IHH) [5], the hypoxia-induced signaling [6], and the Wnt/ β -catenin signaling [7–9] induce hypertrophic differentiation of chondrocytes and the subsequent aggravation of OA. Indeed, conditional activation of β -catenin in articular chondrocytes in adult mice leads to premature chondrocyte differentiation and development of an OA-like phenotype [10]. In addition, β -catenin stimulates activity of the ECM catabolic enzymes in articular chondrocytes [11]. We thus sought for a modality to suppress Wnt/ β -catenin signaling as a potential therapeutic target for OA.

Extracellular antagonists of Wnt, such as the secreted frizzled-related proteins (SFRPs), the dickkopf (DKKs), and sclerostin (SOST), have been studied in model animals and patients with OA [12–14]. One of the SFRPs, FRZB (also known as SFRP3), is a Wnt antagonist originally identified as a chondrogenic factor in articular cartilage extracts [15]. An amino acid-substituting single nucleotide polymorphism (SNP) in FRZB is associated with hip OA [16]. *Frzb*-knockout mice are susceptible to a collagenase-induced OA [12]. FRZB functions as a natural brake on hypertrophic differentiation of articular cartilage [17]. FRZB is thus expected to serve as a potential therapeutic mediator against OA progression.




Figure 1. Verapamil activates *FRZB* promoter and reduces Wnt/ β -catenin signaling. Luciferase activities in human chondrosarcoma (HCS) cells treated with the indicated concentrations of verapamil for 24 hrs. Firefly luciferase activity for *FRZB* promoter (A) or TOPFlash reporter activity (B) are normalized by the TK promoter-driven Renilla luciferase activity and expressed as relative luciferase units. The mean and SEM ($n=12$) are indicated. ** $p<0.01$ and * $p<0.05$ versus control by one-way ANOVA with Tukey's test. doi:10.1371/journal.pone.0092699.g001

Drug repositioning strategy, in which a drug already used for a specific disease is applied to treat another disease, has been gaining increased attention from both academia and industry in recent years [18,19]. The advantage of this strategy is that the identified drugs can be readily applied to clinical practice, because the optimal doses, adverse effects, and contraindications are already established.

Here, we screened FDA-approved compounds to identify a clinically applicable drug that induces *FRZB* gene expression and downregulates Wnt/ β -catenin signaling. We identified that one of calcium channel blockers, verapamil, but not other blockers upregulates expression of the *FRZB* gene and induces chondrogenic markers. In chondrogenically differentiated ATDC5 and explants of mouse tibiae, verapamil blocks nuclear localization of β -catenin and induces proteoglycan production. Finally, articular injection of verapamil ameliorated cartilage damages in OA-induced knees in rat model.

Materials and Methods

Screening of FDA-approved drugs with dual luciferase reporter assay

The *FRZB* promoter region (positions $-2,218$ to -1 immediately upstream of the ATG translation start site) was amplified with primers, 5'-ccgCTCGAGTGTAGACCAGGCAAAGTTTGTA-3' and 5'-ggaAGATCTGGATCTGGGAGCTTCTCCTC-3', from human genomic DNA isolated from HEK293 cells, in which the 5' overhangs are indicated by lower case letters and the XhoI and BglII sites are underlined. The amplicon was cloned into pGL4.10-luc2 luciferase vector (Promega) using XhoI and BglII sites (pGL4.10-*FRZB*). Human chondrosarcoma (HCS-2/8) cells were kindly provided by Dr. Masaharu Takigawa at Okayama University [20], and were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Thermo Scientific). For the *FRZB* promoter assay, $\sim 1 \times 10^4$ cells were seeded in 96-well culture plates (Falcon) and were transfected with the pGL4.10-*FRZB* as well as phRL-TK encoding Renilla luciferase (Promega) using Fugene6 (Invitrogen) according to the manufacturer's protocols. For measuring β -catenin-mediated transcriptional activation, HCS-2/8 cells were transfected with TOPFlash firefly

luciferase reporter vector (M50 Super 8 \times TOPFlash plasmid, Addgene) and phRL-TK. At 24 hours after transfection, the cells were incubated for 24 additional hours in the presence of 10 μ M of 1,186 FDA-approved chemical compounds (Prestwick Chemical). Luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega) and PowerScan4 (DS Parma Biomedical). Firefly luciferase activity was normalized by Renilla luciferase activity and relative luciferase units (RLU) are indicated.

Total RNA extraction and real-time RT-PCR analysis

The human studies including using HCS-2/8 cells were approved by the Ethical Review Committee of the Nagoya University Graduate School of Medicine. Human osteoarthritic chondrocyte (OAC) cells were obtained from patients who underwent joint replacement for knee OA after appropriate written informed consent was obtained. The conditioned medium enriched with mouse Wnt3A (Wnt3A-CM) was harvested from L Wnt-3A cells (CRL-2647, ATCC) that stably expressed mouse Wnt3a. OAC cells were treated with variable combinations of verapamil, recombinant human Wnt3A (R&D systems), Wnt3A-CM, and 20 mM LiCl. Total RNA was isolated from OAC cells using Trizol (Life Technologies). The first strand cDNA was synthesized with ReverTra Ace (Toyobo). We quantified mRNAs for *FRZB*, *ACAN*, *COL2A1*, *SOX9*, *AXIN2*, and *MMP3* using LightCycler 480 Real-Time PCR (Roche) and SYBR Green (Takara). The mRNA levels were normalized for that of *GAPDH*.

Knockdown of *FRZB* using siRNA

OAC cells were transfected with siFRZB-1 (5'-GGCUAAA-GUUAAGAGAU-3' and 5'-UAUCUCUUUAACUUUAGC-C-3') or siFRZB-2 (5'-GGAUCGACUCGGUAAAAA-3' and 5'-UUUUUUACCGAGUCGAUC-3') using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocols. Four hours after transfection, the medium was changed to fresh DMEM with 10% FBS, and cells were treated with Wnt3A-CM and 25 μ M of verapamil.

Western blotting

OAC cells were treated with Wnt3A-CM as well as with 0, 2.5, 5, 10, and 25 μ M of verapamil. After 72 hours, cells were lysed in